Literature DB >> 7854224

Juvenile myoclonic epilepsy: diagnosis, management and outcome.

C Sharpe1, N Buchanan.   

Abstract

OBJECTIVES: To study delay in diagnosis, seizure control, seizure-provoking factors, suitable medications and drug side effects in patients with juvenile myoclonic epilepsy.
DESIGN: Telephone and personal interview of patients and review of their clinical notes. PARTICIPANTS AND
SETTING: Thirty-six patients attending an epilepsy clinic at a tertiary referral hospital.
RESULTS: There was a substantial delay in the diagnosis of juvenile myoclonic epilepsy because the symptom of early-morning myoclonus was not specifically sought. Sodium valproate is the drug of choice, producing absolute seizure control in 63% of cases (19/30). Most patients with poor seizure control had provoked seizures only, emphasising the importance of lifestyle in management. Half of the patients taking sodium valproate experienced side effects, such as weight gain. Lamotrigine is the most suitable alternative.
CONCLUSIONS: Juvenile myoclonic epilepsy is a common, under-recognised form of epilepsy which is best treated with sodium valproate. If side effects occur, lamotrigine should be used.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7854224     DOI: 10.5694/j.1326-5377.1995.tb138476.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  3 in total

1.  Ultrastructure of Purkinje cell perikarya and their dendritic processes in the rat cerebellar cortex in experimental encephalopathy induced by chronic application of valproate.

Authors:  M E Sobaniec-Lotowska
Journal:  Int J Exp Pathol       Date:  2001-12       Impact factor: 1.925

Review 2.  [Medical treatment of epilepsy: hidden dimensions].

Authors:  J Bauer; C Kronisch
Journal:  Nervenarzt       Date:  2009-04       Impact factor: 1.214

3.  [Epilepsy and driving. Background, new German guidelines and comments].

Authors:  J Bauer; M Neumann
Journal:  Nervenarzt       Date:  2009-12       Impact factor: 1.214

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.